image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 10.46
-3.8 %
$ 665 M
Market Cap
-12.81
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one EOLS stock under the worst case scenario is HIDDEN Compared to the current market price of 10.5 USD, Evolus, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one EOLS stock under the base case scenario is HIDDEN Compared to the current market price of 10.5 USD, Evolus, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one EOLS stock under the best case scenario is HIDDEN Compared to the current market price of 10.5 USD, Evolus, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EOLS

image
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
264 M REVENUE
30.79%
-34.4 M OPERATING INCOME
30.11%
-50.4 M NET INCOME
18.26%
-18 M OPERATING CASH FLOW
47.07%
-4.82 M INVESTING CASH FLOW
-196.44%
47.4 M FINANCING CASH FLOW
6.21%
78.9 M REVENUE
29.24%
-2.31 M OPERATING INCOME
85.04%
-6.79 M NET INCOME
64.57%
4.81 M OPERATING CASH FLOW
184.03%
-1.36 M INVESTING CASH FLOW
3.40%
-1.31 M FINANCING CASH FLOW
7.27%
Balance Sheet Evolus, Inc.
image
Current Assets 151 M
Cash & Short-Term Investments 87 M
Receivables 47.7 M
Other Current Assets 16.7 M
Non-Current Assets 81.2 M
Long-Term Investments 0
PP&E 10.4 M
Other Non-Current Assets 70.8 M
37.39 %20.50 %7.18 %4.47 %30.45 %Total Assets$232.6m
Current Liabilities 63 M
Accounts Payable 9.24 M
Short-Term Debt 3.44 M
Other Current Liabilities 50.3 M
Non-Current Liabilities 164 M
Long-Term Debt 6.76 M
Other Non-Current Liabilities 157 M
4.07 %22.15 %2.98 %69.29 %Total Liabilities$227.0m
EFFICIENCY
Earnings Waterfall Evolus, Inc.
image
Revenue 264 M
Cost Of Revenue 84 M
Gross Profit 180 M
Operating Expenses 217 M
Operating Income -34.4 M
Other Expenses 16 M
Net Income -50.4 M
300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)264m(84m)180m(217m)(34m)(16m)(50m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.23% GROSS MARGIN
68.23%
-13.02% OPERATING MARGIN
-13.02%
-19.08% NET MARGIN
-19.08%
-913.07% ROE
-913.07%
-21.68% ROA
-21.68%
-20.15% ROIC
-20.15%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Evolus, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -50.4 M
Depreciation & Amortization 6.02 M
Capital Expenditures -1.47 M
Stock-Based Compensation 22.3 M
Change in Working Capital 0
Others 4.17 M
Free Cash Flow -19.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Evolus, Inc.
image
Wall Street analysts predict an average 1-year price target for EOLS of $24 , with forecasts ranging from a low of $20 to a high of $27 .
EOLS Lowest Price Target Wall Street Target
20 USD 91.20%
EOLS Average Price Target Wall Street Target
24 USD 129.45%
EOLS Highest Price Target Wall Street Target
27 USD 158.13%
Price
Max Price Target
Min Price Target
Average Price Target
282826262424222220201818161614141212101088Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Evolus, Inc.
image
Sold
0-3 MONTHS
2.16 M USD 5
3-6 MONTHS
156 K USD 3
6-9 MONTHS
138 K USD 2
9-12 MONTHS
6.87 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April of an aggregate of 30,579 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant d. businesswire.com - 2 weeks ago
Evolus Announces Commercial Launch of Evolysse™ NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for health. businesswire.com - 2 weeks ago
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the launch of its bold new campaign, “Drop the F Word,” ahead of the upcoming commercial launch of Evolysse™. Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse™, a collection of injectable hyaluronic acid (HA) gels specifically designed to deliver long-lasting, natural. businesswire.com - 2 weeks ago
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1. The fireside chats can be accessed on the Investor Relations page of the Evolus website here. businesswire.com - 1 month ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company's common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant and vesting commencement d. businesswire.com - 1 month ago
Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript Evolus, Inc. (NASDAQ:EOLS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - Chief Medical Officer and Head of R&D Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Gangireddy Madhumitha - Stryker Navann Ty - BNP Paribas Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon, everyone, and thank you for standing by. seekingalpha.com - 1 month ago
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago. zacks.com - 1 month ago
Evolus posts quarterly profit on strong sales of cosmetic injection Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox. reuters.com - 1 month ago
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full-year ended December 31, 2024. “We reached a significant inflection point in 2024, achieving full-year profitability1 ahead of expectations while delivering our fifth consecutive year of revenue growth exceeding 30%,” said David Moatazedi, President and Chief Executive Officer of Ev. businesswire.com - 1 month ago
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on Thursday, February 27, 2025. As part of the event, David Moatazedi, President and CEO of Evolus, will host a fireside chat on Thursday, February 27, 2025, from 9:30 AM – 10:00 AM ET. A live we. businesswire.com - 2 months ago
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's r. businesswire.com - 2 months ago
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 2 months ago
8. Profile Summary

Evolus, Inc. EOLS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 665 M
Dividend Yield 0.00%
Description Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Contact 520 Newport Center Drive, Newport Beach, CA, 92660 https://www.evolus.com
IPO Date Feb. 8, 2018
Employees 332
Officers Mr. David Moatazedi President, Chief Executive Officer & Director Mr. Jeffrey J. Plumer General Counsel Mr. Nareg Sagherian Head of Global Investor Relations & Corporate Communications Ms. Jessica Novak Senior Vice President of Human Resources Mr. Kurt Knab Senior Vice President of Sales Ms. Tomoko Yamagishi-Dressler Chief Marketing Officer Ms. Sandra Beaver Chief Financial Officer Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. Chief Medical Officer and Head of Research & Development